Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium

Microvascular endothelial damage underlies the pathological changes in haemorrhagic colitis and the haemolytic uraemic syndrome (HUS) caused by enterohaemorrhagic Escherichia coli (EHEC). Shiga toxins (Stxs) are presently the best characterised EHEC virulence factors that can cause the microvascular endothelium injury. Stxs are released by EHEC in the intestine, absorbed across the gut epithelium into the circulation, and transported to small vessel endothelial cells. Then, they presumably injure the host cell by inhibiting protein synthesis, stimulating prothrombotic messages, or inducing apoptosis. The net result is a multi-organ thrombotic process. Moreover, Stxs stimulate a variety of non-endothelial cells to produce and secrete inflammatory mediators (cytokines, chemokines, adhesion molecules) which could potentiate the effects of Stxs on endothelial cells. The association of HUS with Stx-negative E. coli strains stimulated intensive research on putative non-Stx virulence factors, which might also contribute to the pathogenesis of HUS and haemorrhagic colitis. Based on current data, cytolethal distending toxin, EHEC haemolysin, and subtilase cytotoxin might be such candidates.

[1]  A. Mellmann,et al.  Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  H. Karch,et al.  Molecular Profiling and Phenotype Analysis of Escherichia coli O26:H11 and O26:NM: Secular and Geographic Consistency of Enterohemorrhagic and Enteropathogenic Isolates , 2005, Journal of Clinical Microbiology.

[3]  P. Tarr,et al.  Shiga-toxin-producing and haemolytic uraemic syndrome , 2005 .

[4]  R. Cherla,et al.  Comparative evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccharides in human monocytic and macrophage-like cells. , 2005, Microbial pathogenesis.

[5]  M. Menger,et al.  Intravital fluorescence microscopy: a novel tool for the study of the interaction of Staphylococcus aureus with the microvascular endothelium in vivo. , 2005, The Journal of infectious diseases.

[6]  F. Taieb,et al.  Bacterial toxins that modulate host cell-cycle progression. , 2005, Current opinion in microbiology.

[7]  H. Karch,et al.  Cytolethal Distending Toxin from Shiga Toxin-Producing Escherichia coli O157 Causes Irreversible G2/M Arrest, Inhibition of Proliferation, and Death of Human Endothelial Cells , 2005, Infection and Immunity.

[8]  A. Friedrich,et al.  Transcriptional Analysis of Genes Encoding Shiga Toxin 2 and Its Variants in Escherichia coli , 2005, Applied and Environmental Microbiology.

[9]  A. Friedrich,et al.  A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli. , 2004, Molecular nutrition & food research.

[10]  A. Macconnachie,et al.  Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection , 2004, Current opinion in infectious diseases.

[11]  A. Caprioli,et al.  Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome , 2004, Cytometry. Part B, Clinical cytometry.

[12]  P. Srimanote,et al.  A New Family of Potent AB5 Cytotoxins Produced by Shiga Toxigenic Escherichia coli , 2004, The Journal of experimental medicine.

[13]  K. Friedman,et al.  Lepirudin prevents lethal effects of Shiga toxin in a canine model , 2004, Thrombosis and Haemostasis.

[14]  V. L. Tesh,et al.  Regulation of Proinflammatory Cytokine Expression by Shiga Toxin 1 and/or Lipopolysaccharides in the Human Monocytic Cell Line THP-1 , 2004, Infection and Immunity.

[15]  D. Newburg,et al.  Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. , 2004, Microbial pathogenesis.

[16]  H. Karch,et al.  Phenotypic and Genotypic Analyses of Enterohemorrhagic Escherichia coli O145 Strains from Patients in Germany , 2004, Journal of Clinical Microbiology.

[17]  H. Karch,et al.  Characterization of Cytolethal Distending Toxin Genes and Expression in Shiga Toxin-Producing Escherichia coli Strains of Non-O157 Serogroups , 2004, Infection and Immunity.

[18]  M. Karmali Infection by shiga toxin-producing Escherichia coli , 2004, Molecular biotechnology.

[19]  M. Karmali Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. , 2004, The Journal of infectious diseases.

[20]  H. Thysell,et al.  Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura , 1995, Pediatric Nephrology.

[21]  T. Barratt,et al.  The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome , 1989, Pediatric Nephrology.

[22]  R. Cherla,et al.  Shiga toxins and apoptosis. , 2003, FEMS microbiology letters.

[23]  E. Hansen,et al.  A CdtA-CdtC Complex Can Block Killing of HeLa Cells by Haemophilus ducreyi Cytolethal Distending Toxin , 2003, Infection and Immunity.

[24]  S. McColl,et al.  Enhanced CXC Chemokine Responses of Human Colonic Epithelial Cells to Locus of Enterocyte Effacement-Negative Shiga-Toxigenic Escherichia coli , 2003, Infection and Immunity.

[25]  T. Uchida STX-liposome conjugates as candidate vaccines. , 2003, Drugs of today.

[26]  F. Gunzer,et al.  Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. , 2003, Blood.

[27]  H. Karch,et al.  Cytolethal Distending Toxin Gene Cluster in Enterohemorrhagic Escherichiacoli O157:H− and O157:H7: Characterization and Evolutionary Considerations , 2003, Infection and Immunity.

[28]  A. Friedrich,et al.  Shiga Toxin 1c-Producing Escherichia coli Strains: Phenotypic and Genetic Characterization and Association with Human Disease , 2003, Journal of Clinical Microbiology.

[29]  C. Buchrieser,et al.  Analysis of Genome Plasticity in Pathogenic and Commensal Escherichia coli Isolates by Use of DNA Arrays , 2003, Journal of bacteriology.

[30]  C. Dehio Recent progress in understanding Bartonella-induced vascular proliferation. , 2003, Current opinion in microbiology.

[31]  C. Lingwood,et al.  Induction by Sphingomyelinase of Shiga Toxin Receptor and Shiga Toxin 2 Sensitivity in Human Microvascular Endothelial Cells , 2003, Infection and Immunity.

[32]  A. Edefonti,et al.  Shiga Toxin–Producing Escherichia coli Infections Associated with Hemolytic Uremic Syndrome, Italy, 1988–2000 , 2003, Emerging infectious diseases.

[33]  C. Lingwood Shiga toxin receptor glycolipid binding. Pathology and utility. , 2003, Methods in molecular medicine.

[34]  M. Bitzan,et al.  Interaction of Shiga toxin with endothelial cells. , 2003, Methods in molecular medicine.

[35]  D. Kohan,et al.  Induction of apoptosis of human brain microvascular endothelial cells by shiga toxin 1. , 2003, The Journal of infectious diseases.

[36]  W. Henderson,et al.  Platelet-activating factor and Escherichia coli O157:H7 infections , 2002, Pediatric Nephrology.

[37]  M. Kagnoff,et al.  Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF‐κB and MAP kinase pathways and the upregulated expression of interleukin 8 , 2002, Cellular microbiology.

[38]  G. Remuzzi,et al.  Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. , 2002, Kidney international.

[39]  H. Karch,et al.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. , 2002, The Journal of infectious diseases.

[40]  Tatsuo Yamamoto,et al.  Enterohemolysin operon of Shiga toxin‐producing Escherichia coli: a virulence function of inflammatory cytokine production from human monocytes , 2002, FEBS letters.

[41]  H. Karch,et al.  Identification, Characterization, and Distribution of a Shiga Toxin 1 Gene Variant (stx1c) in Escherichia coli Strains Isolated from Humans , 2002, Journal of Clinical Microbiology.

[42]  L. Barbieri,et al.  Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells 1 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  P. Tarr Basic fibroblast growth factor and Shiga toxin-O157:H7-associated hemolytic uremic syndrome. , 2002, Journal of the American Society of Nephrology : JASN.

[44]  A. Friedrich,et al.  Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. , 2002, The Journal of infectious diseases.

[45]  D. Acheson,et al.  Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy , 2002, Pediatric Nephrology.

[46]  T. Frisan,et al.  The cytolethal distending toxins induce DNA damage and cell cycle arrest. , 2001, Toxicon : official journal of the International Society on Toxinology.

[47]  D. Acheson,et al.  Shiga Toxins Induce, Superinduce, and Stabilize a Variety of C-X-C Chemokine mRNAs in Intestinal Epithelial Cells, Resulting in Increased Chemokine Expression , 2001, Infection and Immunity.

[48]  P. Murdoch,et al.  The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  D. Acheson,et al.  Shiga Toxin Translocation across Intestinal Epithelial Cells Is Enhanced by Neutrophil Transmigration , 2001, Infection and Immunity.

[50]  G. Remuzzi,et al.  Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. , 2001, Blood.

[51]  E. Seidman,et al.  Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.

[52]  E. Elliott,et al.  Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features , 2001, Archives of disease in childhood.

[53]  J. Galán,et al.  CdtA, CdtB, and CdtC Form a Tripartite Complex That Is Required for Cytolethal Distending Toxin Activity , 2001, Infection and Immunity.

[54]  C. Dehio Bartonella interactions with endothelial cells and erythrocytes. , 2001, Trends in microbiology.

[55]  H. Karch,et al.  Sorbitol-Fermenting Shiga Toxin-Producing Escherichia coli O157:H− Strains: Epidemiology, Phenotypic and Molecular Characteristics, and Microbiological Diagnosis , 2001, Journal of Clinical Microbiology.

[56]  K. Nilsson,et al.  Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. , 2001, Blood.

[57]  E. O'Loughlin,et al.  Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. , 2001, Microbes and infection.

[58]  Craig S. Wong,et al.  Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.

[59]  L. V. D. Heuvel,et al.  Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. , 2001, Journal of the American Society of Nephrology : JASN.

[60]  J. H. Green,et al.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. , 2001, The Journal of infectious diseases.

[61]  V. V. van Hinsbergh,et al.  Verocytotoxin-induced apoptosis of human microvascular endothelial cells. , 2001, Journal of the American Society of Nephrology : JASN.

[62]  K. Sandvig Shiga toxins. , 2001, Toxicon : official journal of the International Society on Toxinology.

[63]  J. Galán,et al.  A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. , 2000, Science.

[64]  T. Higuchi,et al.  Verotoxin-1 Induces Tissue Factor Expression in Human Umbilical Vein Endothelial Cells through Activation of NF-κB/Rel and AP-1 , 2000, Thrombosis and Haemostasis.

[65]  C. Elwell,et al.  DNase I homologous residues in CdtB are critical for cytolethal distending toxin‐mediated cell cycle arrest , 2000, Molecular microbiology.

[66]  F. Proulx,et al.  Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic‐uremic syndrome , 2000, The Pediatric infectious disease journal.

[67]  Craig S. Wong,et al.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.

[68]  V. V. van Hinsbergh,et al.  Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. , 2000, Blood.

[69]  E. Seidman,et al.  Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[70]  N. Koide,et al.  Primary cultures of human endothelial cells are susceptible to low doses of Shiga toxins and undergo apoptosis. , 1999, The Journal of infectious diseases.

[71]  M. Frosch,et al.  Escherichia coli O157:H7 and O157:H−Strains That Do Not Produce Shiga Toxin: Phenotypic and Genetic Characterization of Isolates Associated with Diarrhea and Hemolytic-Uremic Syndrome , 1999, Journal of Clinical Microbiology.

[72]  H. Kondo,et al.  Inhibition of Neutrophil Apoptosis by Verotoxin 2 Derived from Escherichia coli O157:H7 , 1999, Infection and Immunity.

[73]  D. Acheson,et al.  Shiga Toxins Stimulate Secretion of Interleukin-8 from Intestinal Epithelial Cells , 1999, Infection and Immunity.

[74]  J. Samuel,et al.  Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. , 1999, The Journal of infectious diseases.

[75]  J. Lanser,et al.  Molecular Characterization of a Shiga ToxigenicEscherichia coli O113:H21 Strain Lacking eaeResponsible for a Cluster of Cases of Hemolytic-Uremic Syndrome , 1999, Journal of Clinical Microbiology.

[76]  A. Blann,et al.  Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome , 1999, Pediatric Nephrology.

[77]  H. Karch,et al.  Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. , 1999, Diagnostic microbiology and infectious disease.

[78]  J. Harlan,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Endothelial Cells Undergoing Apoptosis Become Proadhesive for Nonactivated Platelets , 1999 .

[79]  Y. Ihara,et al.  Localization of verotoxin receptors in nervous system , 1999, Brain Research.

[80]  H. Miyata,et al.  [Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection]. , 1999, Nihon Jinzo Gakkai shi.

[81]  T. Pysher,et al.  Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. , 1999, The American journal of pathology.

[82]  D. Acheson,et al.  Responses of Human Intestinal Microvascular Endothelial Cells to Shiga Toxins 1 and 2 and Pathogenesis of Hemorrhagic Colitis , 1999, Infection and Immunity.

[83]  S. McEwen,et al.  Associations between Virulence Factors of Shiga Toxin-ProducingEscherichia coli and Disease in Humans , 1999, Journal of Clinical Microbiology.

[84]  S. Lauwers,et al.  Identification of New Verocytotoxin Type 2 Variant B-Subunit Genes in Human and Animal Escherichia coliIsolates , 1998, Journal of Clinical Microbiology.

[85]  J. Vermylen,et al.  Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. , 1998, Kidney international.

[86]  E. Seidman,et al.  Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. , 1998, The Pediatric infectious disease journal.

[87]  P. Stricklett,et al.  Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. , 1998, Kidney international.

[88]  H. Abboud,et al.  Shiga toxin 1 elicits diverse biologic responses in mesangial cells. , 1998, Kidney international.

[89]  U. Querfeld,et al.  A 12-year-old boy with fatal hemolytic-uremic-syndrome, excessive neutrophilia and elevated endogenous granulocyte-colony-stimulating-factor serum concentrations. , 1998, Clinical nephrology.

[90]  L. Monnens,et al.  Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels in Urine and Serum of Patents with Hemolytic Uremic Syndrome , 1998, Pediatric Research.

[91]  Yang Wang,et al.  Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. , 1998, The Journal of clinical investigation.

[92]  G. Haycock,et al.  Activation of Coagulation and Fibrinolysis in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome , 1997, Thrombosis and Haemostasis.

[93]  D. Milford,et al.  Delays in the diagnosis of oesophagogastric cancer: a consecutive case series , 1997, BMJ.

[94]  D. Adu,et al.  Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection , 1997, Archives of disease in childhood.

[95]  M. Petric,et al.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits , 1997, Infection and immunity.

[96]  B. Bell,et al.  Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. , 1997, Pediatrics.

[97]  H. Karch,et al.  EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V , 1997, Molecular microbiology.

[98]  V. V. van Hinsbergh,et al.  Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. , 1997, Kidney international.

[99]  R. Benz,et al.  Pore-forming properties of the plasmid-encoded hemolysin of enterohemorrhagic Escherichia coli O157:H7. , 1996, European journal of biochemistry.

[100]  T. Beattie,et al.  The neutrophil oxidative burst in diarrhoea – associated haemolytic uraemic syndrome , 1996, Pediatric Nephrology.

[101]  V. V. van Hinsbergh,et al.  Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. , 1996, Blood.

[102]  D. Acheson,et al.  Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. , 1996, The Journal of infectious diseases.

[103]  A. O’Brien,et al.  Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice , 1996, Infection and immunity.

[104]  G. Remuzzi,et al.  Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. , 1995, Blood.

[105]  T. Obrig,et al.  Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. , 1995, The Journal of infectious diseases.

[106]  L. Beutin,et al.  Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.

[107]  V. V. van Hinsbergh,et al.  Plasma cytokine levels in hemolytic uremic syndrome. , 1995, Nephron.

[108]  J. Wells,et al.  A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. , 1994, JAMA.

[109]  L. Monnens,et al.  The Fibrinolytic System in the Hemolytic Uremic Syndrome: In Vivo and In Vitro Studies , 1994, Pediatric Research.

[110]  C. Lingwood,et al.  Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro , 1993, Infection and immunity.

[111]  C. Lingwood,et al.  Endothelial heterogeneity in Shiga toxin receptors and responses. , 1993, The Journal of biological chemistry.

[112]  V. Jay,et al.  Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.

[113]  T. Barratt,et al.  Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. , 1992, Kidney international.

[114]  N. Bang,et al.  Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome , 1992 .

[115]  T. Obrig,et al.  Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro , 1992, Infection and immunity.

[116]  M. P. Jackson,et al.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.

[117]  M. McKee,et al.  Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 , 1991, Infection and immunity.

[118]  B. Rowe,et al.  Changes in the postenteropathic form of the hemolytic uremic syndrome in children. , 1991, Clinical nephrology.

[119]  J. Wells,et al.  Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. , 1990, The Journal of pediatrics.

[120]  R. Petras,et al.  Escherichia coli O157:H7-associated colitis. A clinical and histological study of 11 cases. , 1990, Gastroenterology.

[121]  S. Ostroff,et al.  Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. , 1989, The Journal of infectious diseases.

[122]  K. Forsyth,et al.  NEUTROPHIL-MEDIATED ENDOTHELIAL INJURY IN HAEMOLYTIC URAEMIC SYNDROME , 1989, The Lancet.

[123]  J. Brown,et al.  Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1 , 1989, The Journal of cell biology.

[124]  M. Karmali,et al.  Infection by verocytotoxin-producing Escherichia coli , 1989, Clinical Microbiology Reviews.

[125]  C. Lingwood,et al.  Verotoxin receptor glycolipid in human renal tissue. , 1989, Nephron.

[126]  M. P. Jackson,et al.  Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine , 1988, Journal of bacteriology.

[127]  L. Becker,et al.  The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. , 1988, Human pathology.

[128]  J. Brown,et al.  Direct cytotoxic action of Shiga toxin on human vascular endothelial cells , 1988, Infection and immunity.

[129]  T. Yutsudo,et al.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. , 1988, European journal of biochemistry.

[130]  M. P. Jackson,et al.  Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933 , 1987 .

[131]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.

[132]  M. Petric,et al.  SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.

[133]  M. Kashgarian,et al.  The importance of nonrenal involvement in hemolytic-uremic syndrome. , 1980, Pediatrics.

[134]  G. Striker,et al.  Renal microangiopathy of the hemolytic-uremic syndrome in childhood. , 1976, Nephron.